济川药业: 湖北济川药业股份有限公司关于公司控股股东股权结构变动暨公司增加实际控制人的提示性公告

Core Viewpoint - The announcement details a change in the shareholding structure of Hubei Jichuan Pharmaceutical Co., Ltd., where the actual controller changes from Mr. Cao Longxiang to Mr. Cao Fei and Mr. Cao Longxiang due to a family internal asset arrangement [1][3]. Group 1: Shareholding Structure Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jichuan Holdings to his son, Mr. Cao Fei, resulting in Mr. Cao Longxiang holding 40% and Mr. Cao Fei holding 60% of Jichuan Holdings [1][3]. - As of the announcement date, Jichuan Holdings holds 416,757,360 shares of the company, accounting for 45.22% of the total share capital [1]. - The combined shareholding of Jichuan Holdings and its concerted actors, including Tibet Jichuan Enterprise Management Co., Ltd. and Mr. Cao Longxiang, totals 563,595,818 shares, representing 61.15% of the total share capital [1]. Group 2: Impact of Changes - The change in shareholding structure does not alter the controlling shareholder, which remains Jichuan Holdings, and the actual controllers are now Mr. Cao Fei and Mr. Cao Longxiang [2][3]. - The internal asset arrangement will not affect the company's operational stability, independence, or ongoing viability [2][3]. - Following the share transfer, Mr. Cao Fei will hold 56.07% of the company's shares through Jichuan Holdings and Tibet Jichuan, triggering his obligation for a mandatory tender offer [3][4].